Arfolitixorin
A drug being studied in colorectal cancer trials. It appears in 2 clinical trials.
What it is
Arfolitixorin is a folate analog that serves as an enhanced replacement for leucovorin (folinic acid) in colorectal cancer chemotherapy regimens. It functions as a reduced folate cofactor that potentiates the cytotoxic activity of 5-fluorouracil by stabilizing the binding of 5-FU metabolites to thymidylate synthase. Arfolitixorin is used in combination with 5-fluorouracil, oxaliplatin, and bevacizumab (FOLFOX-based regimens) for the treatment of metastatic colorectal cancer. This agent represents a next-generation folate rescue compound designed to provide more consistent and potent enhancement of fluoropyrimidine efficacy compared to standard leucovorin.
How it works
Arfolitixorin is rapidly converted to the active reduced folate 5,10-methylenetetrahydrofolate within cancer cells. This active metabolite enhances the formation and stability of the ternary complex between fluorodeoxyuridine monophosphate (the active metabolite of 5-FU), thymidylate synthase, and the folate cofactor, leading to more effective inhibition of DNA synthesis and enhanced tumor cell death.
Molecular targets
Common side effects
Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.
Trials with this drug
1 recruitingGuides that may help
Written for patients and families, in plain language.